TABLE 3.
Antiviral activity of glecaprevir against HCV replicon cells containing HCV proteases from HCV-infected patients
| HCV subtype | NS3 amino acid polymorphisma | No. of samples | EC50 (nM)b |
||
|---|---|---|---|---|---|
| Median | IQRc | Range | |||
| 1a | Noned | 5 | 0.06 | 0.03 | 0.05–0.12 |
| 1a | Q80K | 5 | 0.09 | 0.02 | 0.07–0.10 |
| 1a | Q80N | 1 | 0.09 | ||
| 1b | None | 9 | 0.29 | 0.20 | 0.20–0.68 |
| 2a | None | 4 | 1.6 | 0.42 | 0.66–1.9 |
| 2b | None | 4 | 2.2 | 1.0 | 1.4–3.2 |
| 3a | None | 2 | 2.3 | 1.6 | 0.71–3.8 |
| 4a | None | 5 | 0.39 | 0.15 | 0.31–0.55 |
| 4a | T54S | 1 | 0.44 | ||
| 4d | None | 3 | 0.17 | 0.06 | 0.13–0.25 |
| 5a | None | 1 | 0.12 | ||
a
NS3 amino acid polymorphisms were assessed at amino acid positions 36, 43, 54, 55, 56, 80, 122, 155, 156, and 168 relative to the respective subtype-specific reference sequence.
b
Values were determined in ≥3 independent transient-transfection assays.
c
IQR, interquartile range.
d
None, there were no polymorphisms relative to the subtype-specific reference sequence at the amino acid positions assessed.